Targeting Inflammation to Reduce Residual Cardiovascular Risk.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing findings from existing randomized trials without systematic review methodology.
PubMed 32880743 · doi:10.1007/s11883-020-00883-3
What was done
This narrative review summarizes clinical trial evidence evaluating whether targeting vascular inflammation lowers residual cardiovascular risk in patients with established cardiovascular disease. It specifically examines results from three major randomized trials: CANTOS (canakinumab), COLCOT (colchicine), and CIRT (low-dose methotrexate).
What was found
In CANTOS (patients with prior myocardial infarction and high-sensitivity C-reactive protein ≥ 2 mg/L), canakinumab reduced major adverse cardiovascular events (MACE) by 15% (HR 0.85, 95% CI 0.74–0.98). In COLCOT (patients with recent acute coronary syndrome), colchicine 0.5 mg daily yielded a 23% relative risk reduction in major vascular events (HR 0.77, 95% CI 0.61–0.96). In contrast, CIRT was stopped early due to a lack of benefit of low-dose methotrexate for MACE reduction in patients with coronary artery disease and either type 2 diabetes or metabolic syndrome.
Why it matters
These trial results demonstrate that targeting specific vascular inflammatory pathways can successfully lower residual risk for recurrent cardiovascular events in secondary prevention populations.
Limits
The abstract describes a narrative review rather than a systematic review or meta-analysis. It omits participant sample sizes, trial durations, safety outcomes, adverse effects, and detailed clinical inclusion criteria.
Cited by
- context Strokes and heart attacks are vascular events primarily caused by vascular inflammation stemming from unrecognized metabolic disease.